Caroline M.P.W. Mandigers

Author

Also Known As

Anne S. R. van Lindert, Caroline M Mandigers, Caroline M P W Mandigers, Caroline M. Mandigers, Caroline M. P. W. Mandigers, Caroline M.P.W. Mandigers, Caroline MPW Mandigers, Caroline Mandigers, Mathijs Hendriks

Publications

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Canisius-Wilhelmina Ziekenhuis The Netherlands Cancer Institute Radboud University Medical Center Utrecht University

About

Caroline M.P.W. Mandigers is an author at Radboud University Nijmegen specializing in medicine, oncology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.7K
2	Health Sciences	3	3	490
3	Engineering	1	1	306
4	Nursing	1	1	48
5	Biomedical Engineering	1	1	306

Caroline M.P.W. Mandigers

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven, The Lancet Oncology Breast OncologyOncologyDual Her2 BlockadePharmacologyBreast Cancer	2018	413
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man, The Lancet Oncology MedicineProspective Safety AnalysisCancer ManagementPharmacotherapyCancer Treatment	2018	403
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study Michèle Cavo, Francesca Gay, Meral Beksaç, The Lancet Haematology Hematological MalignancyTransplantationMarrow TransplantationMedicineStem Cell Transplantation	2020	377
Upfront Genotyping of <i>DPYD</i>*<i>2A</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis Maarten J. Deenen, Didier Meulendijks, Annemieke Cats, Journal of Clinical Oncology	2015	333
A Novel Method to Compensate for Different Amplification Efficiencies between Patient DNA Samples in Quantitative Real-Time PCR Jules P.P. Meijerink, Caroline M.P.W. Mandigers, Louis van de Locht, Journal of Molecular Diagnostics EngineeringMeasurementDna AnalysisNucleic Acid Amplification TestBiomedical Engineering	2001	306
Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer Annelies H. Boekhout, Jourik A. Gietema, Bojana Milojkovic Kerklaan, JAMA Oncology	2016	189
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven, JAMA Oncology	2021	130
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity Didier Meulendijks, Linda M. Henricks, Bart Jacobs, British Journal of Cancer	2017	119
A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man, European Journal of Cancer Upfront DpydMedicineMetronomic TherapyPharmacologyPharmacotherapy	2018	87
Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma Caroline M.P.W. Mandigers, Jules P.P. Meijerink, E. J. B. M. Mensink, Blood	2001	64

Page 1